Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|March 1, 2021
- Pharmaceutical Technology's In the Lab eNewsletter 03-03-2021
- Volume 16
- Issue 3
Smart Evaporator from BioChromato Improves Lab Productivity
Author(s)Pharmaceutical Technology Editors
The benchtop device provides a sample preparation tool for labs in need of solvent removal directly from liquid chromatography vials or concentration of multiple samples from extraction or fractionation processes.
Advertisement
The BioChromato Smart Evaporator C10 from BioChromato, launched in February 2021, uses Vacuum Vortex Concentration technology to evaporate up to 10 samples in vials in parallel, thus improving lab productivity. Available in four colors, the benchtop device provides a sample preparation tool for labs in need of solvent removal directly from liquid chromatography vials or concentration of multiple samples from extraction or fractionation processes.
Additionally, the Smart Evaporator C10 features safe drying of temperature sensitive compounds, drying of solvent volumes as low as 0.1ml, and drying of samples without solvent bumping or splashing, removing the risk of sample loss and contamination, the company said in a Feb. 10, 2021 press release.
Source: BioChromato
Articles in this issue
over 5 years ago
Oncoming Elemental Impurity Analysisover 5 years ago
What’s New in Compact Lab EquipmentAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement